Semaglutide
Semaglutide
Semaglutide is a GLP-1 receptor agonist that has been FDA-approved in certain prescription medications for weight management and type 2 diabetes. Compounded semaglutide formulations are not FDA-approved, but are prepared by licensed compounding pharmacies under strict quality standards to meet individual patient needs and may be prescribed by licensed providers when medically appropriate and prepared by licensed compounding pharmacies. Many patients choose compounded options because they may provide greater accessibility, lower cost, and more flexible dosing formats, such as injections or oral drops.
How it works
Semaglutide Injections are administered subcutaneously (under the skin) once per week. They mimic the GLP-1 hormone to regulate hunger, improve glucose control, and support long-term weight loss. The injection form provides consistent dosing and is one of the most clinically studied and effective delivery methods.
How to take it
Administer Semaglutide as a once-weekly subcutaneous injection, usually in the abdomen, thigh, or upper arm. Rotate injection sites each week to reduce irritation. This convenient once-weekly dosing makes it easy for patients to stay consistent with their treatment plan.
What are the results?
Patients using Semaglutide Injections can expect significant weight loss supported by extensive clinical studies.
On average, people taking GLP-1 medications experience significant weight loss. Studies have shown that individuals can lose approximately 1.5% of their body weight per week when combined with a reduced-calorie diet and increased physical activity. Based on clinical trials lasting 68 weeks, patients without diabetes who took 2.4 mg/week of Semaglutide saw substantial reductions in weight. This makes Semaglutide a highly effective treatment for long-term weight management when used as prescribed.
